International Journal of Hepatology最新文献

{"title":"Hepatocyte and Islet Cell Cotransplantation on Poly-L-Lactide Matrix for the Treatment of Liver Cirrhosis.","authors":"Siufui Hendrawan, Jennifer Lheman, Nuraeni, Ursula Weber, Hans Ulrich Baer","doi":"10.1155/2020/5410359","DOIUrl":"10.1155/2020/5410359","url":null,"abstract":"<p><p>The human autologous hepatocyte matrix implant is a promising alternative procedure to counter liver damage. We assessed the outcome of human hepatocytes isolation from cirrhotic liver compared to the clinical and histological scores of disease severity. A total of 11 patients with various clinical scores (CTP and MELD) and histological score (Metavir, fibrosis) of liver cirrhosis were included in the hepatocyte matrix implant clinical phase I study. The liver segment and pancreatic tissue were harvested from each patient, and hepatocytes and cells of islets of Langerhans were isolated. The freshly isolated human hepatocytes were coseeded with the islet cells onto poly(l-lactic acid) (PLLA) scaffolds, cultured, and transplanted back into the patient. Human hepatocytes were isolated from 11 cirrhotic liver specimens with a resulting yield of 1.4 ± 0.5 × 10⁶ cells per gram of the liver specimen and a viability rate of 52 ± 13%. It was found that the yield and viability of the liver cells were not correlated with the clinical and histological scores of the liver cirrhosis. A correlation was found between the hepatocyte yield obtained and the average number of hepatocytes counted in 10 microscopic fields of view. More viable cells were obtained from cirrhotic livers caused by chronic hepatitis B as compared to chronic hepatitis C in the same MELD score range. There was no correlation between the clinical and histological disease severity scores of liver cirrhosis and the outcome of hepatocytes isolation. It seems that the yield could depend on the type of hepatitis underlying the cirrhotic tissue. The study was registered at www.clinicaltrial.gov with the study identifier: NCT01335568.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"5410359"},"PeriodicalIF":1.8,"publicationDate":"2020-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38640778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endothelial Dysfunction, a Marker of Atherosclerosis, Is Independent of Metabolic Syndrome in NAFLD Patients.","authors":"Jimmy Narayan,&nbsp;Haribhakti Seba Das,&nbsp;Preetam Nath,&nbsp;Ayaskanta Singh,&nbsp;Debakanta Mishra,&nbsp;Pradeep Kumar Padhi,&nbsp;Shivaram Prasad Singh","doi":"10.1155/2020/1825142","DOIUrl":"https://doi.org/10.1155/2020/1825142","url":null,"abstract":"<p><strong>Background: </strong>The study was designed to assess cardiovascular risk factors flow-mediated dilatation % (FMD%) and carotid intima-media thickness (CIMT) in NAFLD.</p><p><strong>Methods: </strong>126 NAFLD subjects and 31 chronic hepatitis B (CHB) controls were studied. Measuring carotid intima-media thickness (CIMT) and the flow-mediated dilatation % (FMD%) by brachial artery Doppler ultrasound were used to assess atherosclerosis. The risk of cardiac events at 10 years (ROCE 10) was estimated by the Prospective Cardiovascular Munster Study (PROCAM) score.</p><p><strong>Results: </strong>58 of 126 NAFLD have coexistent metabolic syndrome. Mean CIMT was 0.73 ± 0.041 mm among NAFLD with MS, 0.66 ± 0.016 mm among NAFLD without MS, and 0.66 ± 0.037 in controls CHB patients. FMD% in NAFLD with MS was 10.43 ± 3.134%, but was 8.56 ± 3.581% in NAFLD without MS and 17.78 ± 6.051% in controls. PROCAM score of NAFLD with MS was 46.95 ± 6.509 while in NAFLD without MS was 38.2 ± 3.738. Controls had a PROCAM score of 38.13 ± 5.755. ROCE 10 in NAFLD with MS was 13.64 ± 8.568 while NAFLD without MS was 5.55 ± 1.949. Controls have a ROCE 10 of 5.95 ± 3.973. Post hoc analysis showed CIMT was dependent upon MS while FMD% was different between all subgroups hence independent of metabolic syndrome.</p><p><strong>Conclusion: </strong>The markers of endothelial dysfunction are significantly higher in patients with NAFLD than controls.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"1825142"},"PeriodicalIF":1.8,"publicationDate":"2020-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/1825142","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38212375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatocellular Expression of SIRT1 and Its Effect on Hepatocellular Carcinoma Progression: A Future Therapeutic Perspective.","authors":"Meseret Derbew Molla,&nbsp;Gashaw Dessie,&nbsp;Yonas Akalu,&nbsp;Birhanu Ayelign","doi":"10.1155/2020/2374615","DOIUrl":"https://doi.org/10.1155/2020/2374615","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is an aggressive primary hepatic malignancy with a significant morbidity and mortality rate. Although chemotherapy along with surgical incision is believed to be an effective therapeutic approach, to date recurrence is being lifted a major concern. Thus, identifying another best therapeutic approach is becoming the main aim of physicians and scholars. In support of this, recently, several studies reported a significant observation of Sirtuin1 (SIRT1) overexpression in the malignant tumor cells, including HCC. As a result, they believed that overexpression of SIRT1 may have an effect on the progression of HCC by targeting growth and/or apoptotic controlling transcriptional factors/signaling pathways. Similarly, other reports confirmed that SIRT1 inhibition had a direct or indirect role in the control of tumor cell growth and metastasis. Therefore, inhibiting the expression and activity of SIRT1 might have a therapeutic effect to handle HCC. However, there are a limited number of reviews regarding the issue, and here, we summarized hepatocellular expression of SIRT1 and its role on HCC progression.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"2374615"},"PeriodicalIF":1.8,"publicationDate":"2020-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/2374615","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38109789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug Treatment of Patients with Liver Cirrhosis in a Tertiary Hospital in Northern Ghana: Does It Comply with Recommended Guidelines?","authors":"Baba Sulemana Mohammed, Matthew Aidoo","doi":"10.1155/2020/9750194","DOIUrl":"10.1155/2020/9750194","url":null,"abstract":"<p><p>The diverse influence of liver function on drug disposition can lead health-care practitioners to inappropriate drug selection, inappropriate drug dosing, or some level of therapeutic negativism. The aim of this study was to assess how drug prescribing in patients with liver cirrhosis at the Tamale Teaching Hospital comply with recommendations of pharmacotherapy and safety guidelines. A prospective cross-sectional study was conducted from February to July, 2019, at the medical ward of the Tamale Teaching Hospital. A total of 152 liver cirrhotic patients were included in this study. Common etiologies for liver cirrhosis were chronic hepatitis B 80 (52.6%) and chronic hepatitis C 30 (19.7%); about 12.5% of etiologies were unknown. Of the 1842 prescription issued, 69% (1270/1842) were compliant. Of the 572 noncompliant prescriptions, about 32% (183/572) were due to pharmacotherapy and 68% (389/572) due to safety guideline recommendations. There was a substantial number (31%) of prescription noncompliance with recommendations for pharmacotherapy and safety guidelines in liver cirrhotic patients at the tertiary hospital in northern Ghana. Prescribers need to be conscious of the role of the liver in drug elimination and prescribe as recommended by guidelines.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"9750194"},"PeriodicalIF":1.5,"publicationDate":"2020-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38059074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Knowledge of Hepatitis B Virus Infection among Pregnant Women in the Ningo-Prampram District, Ghana.","authors":"Precious Kwablah Kwadzokpui,&nbsp;Elliot Elikplim Akorsu,&nbsp;Albert Abaka-Yawson,&nbsp;Solomon Sosu Quarshie,&nbsp;Stephen Adomako Amankwah,&nbsp;Philip Apraku Tawiah","doi":"10.1155/2020/7965146","DOIUrl":"https://doi.org/10.1155/2020/7965146","url":null,"abstract":"<p><strong>Background: </strong>Hepatitis B virus (HBV) infection has been suggested to play a role in various adverse birth outcomes. The study determined the prevalence as well as knowledge of hepatitis B virus infection among pregnant women in the Ningo-Prampram District of the Greater Accra Region of Ghana.</p><p><strong>Materials and methods: </strong>A cross-sectional study using simple random sampling technique was used to recruit 213 pregnant women receiving antenatal care in three different health facilities (Prampram Polyclinic (PPC), Dangme Community Hospital (DCH), and Old Ningo Health Center (ONHC)) in the Ningo-Prampram District of Ghana from November 2018 to January 2019. A semi-structured questionnaire was used to collect data which included participants' HBsAg test results, sociodemographic and gynaecological characteristics, and their level of knowledge on HBV infection. Knowledge of the participants on HBV infection was classified as either excellent, good, or poor based on their cumulative percentage scores from the questionnaire according to Al Rubaish system of classification.</p><p><strong>Results: </strong>Overall low-intermediate prevalence of HBV infection was 3.3%; however, PPC recorded the highest prevalence of 4.0% while DCH and ONHC recorded 2.82% and 2.50%, respectively. Statistically significant association was observed between HBV infection and the health facility. Majority (77.40%) of the study participants had poor knowledge on HBV infection while only 14 (6.57%) had excellent knowledge on HBV. Regarding excellent knowledge, 8 (11.0%) among the participants were demonstrated by the majority of those who received antenatal care from DCH. Generally, knowledge on HBV and the infection was poor among the study participants. Knowledge on HBV infection was found to be associated with residential status (<i>p</i> = 0.006), educational level (<i>p</i> < 0.001), occupation (<i>p</i> < 0.001), and gestational period (<i>p</i> < 0.001). Participant's knowledge was also significantly associated with the health facility (<i>p</i> = 0.027).</p><p><strong>Conclusion: </strong>HBV infection among pregnant women is prevalent in the Ningo-Prampram District even though the prevalence is not very high. The majority of pregnant women in the Ningo-Prampram District inadequate knowledge on HBV infection and it mode of transmission. Intensive public health education on the HBV infection is required in the district to help prevent and manage future transmissions as well as inform the population about the negative side effects of the virus and the need to prevent it by way of vaccination.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"7965146"},"PeriodicalIF":1.8,"publicationDate":"2020-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/7965146","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37937981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isoniazid and Rifampicin Produce Hepatic Fibrosis through an Oxidative Stress-Dependent Mechanism.","authors":"Ayan Biswas,&nbsp;Suman Santra,&nbsp;Debasree Bishnu,&nbsp;Gopal Krishna Dhali,&nbsp;Abhijit Chowdhury,&nbsp;Amal Santra","doi":"10.1155/2020/6987295","DOIUrl":"https://doi.org/10.1155/2020/6987295","url":null,"abstract":"<p><strong>Methods: </strong>A combined dose of INH (50 mg) and RMP (100 mg) per kg body weight per day was administered to mice by oral gavage, 6 days a week, for 4 to 24 weeks for the assessment of liver injury, oxidative stress, and development of hepatic fibrosis, including demonstration of changes in key fibrogenesis linked pathways and mediators.</p><p><strong>Results: </strong>Progressive increase in markers of hepatic stellate cell (HSC) activation associated with changes in matrix turnover was observed between 12 and 24 weeks of INH-RMP treatment along with the elevation of liver collagen content and significant periportal fibrosis. These were associated with concurrent apoptosis of the hepatocytes, increase in hepatic cytochrome P450 2E1 (CYP2E1), NADPH oxidase (NOX) activity, and development of hepatic oxidative stress.</p><p><strong>Conclusions: </strong>INH-RMP can activate HSC through generation of NOX-mediated oxidative stress, leading to the development of liver fibrosis.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"6987295"},"PeriodicalIF":1.8,"publicationDate":"2020-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/6987295","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37904618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Many Difficulties and Subtleties in the Cognitive Assessment of Chronic Hepatitis C Infection.","authors":"Jefferson Abrantes,&nbsp;Daniel Simplicio Torres,&nbsp;Carlos Eduardo Brandão-Mello","doi":"10.1155/2020/9675235","DOIUrl":"https://doi.org/10.1155/2020/9675235","url":null,"abstract":"<p><p>Since the discovery of HCV in 1989, several diseases have been related to chronic infection by this virus. Often, patients with hepatitis C virus (HCV) complain of cognitive impairment even before the development of hepatic cirrhosis, which they described as \"brain fog.\" Several studies have proposed a link between chronic HCV infection and the development of cognitive alterations, but the inclusion of confounding factors in their samples significantly limits the analysis of the results. In this article, we will give an overview about cognitive dysfunction in patients with HCV.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"9675235"},"PeriodicalIF":1.8,"publicationDate":"2020-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/9675235","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37808611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fecal Microbiota Transplantation for Clostridioides Difficile Infection in Patients with Chronic Liver Disease.","authors":"Alireza Meighani,&nbsp;Maryam Alimirah,&nbsp;Mayur Ramesh,&nbsp;Reena Salgia","doi":"10.1155/2020/1874570","DOIUrl":"https://doi.org/10.1155/2020/1874570","url":null,"abstract":"<p><strong>Background: </strong>Fecal microbiota transplantation (FMT) is a well-established therapeutic option for patients with antibiotic resistant <i>Clostridioides difficile</i> infection (CDI). However, the efficacy of FMT in patients with chronic liver disease remains elusive.</p><p><strong>Aims: </strong>We studied the effect of FMT on chronic liver disease (CLD) patients with CDI at our tertiary medical center.</p><p><strong>Methods: </strong>A cohort of all patients who received FMT from December 2012 to May 2014 for refractory or recurrent CDI was identified. Patients were monitored for a year after FMT. Descriptive analysis was conducted to compare the effect of FMT in patients with and without CLD.</p><p><strong>Results: </strong>A total of 201 patients with CDI received FMT, 14 of which had a history of CLD. Nine of these patients exhibited cirrhosis of the liver with a mean Child-Turcotte-Pugh score of 8. CDI development in these patients was associated with recent exposure to antibiotics and was observed to be significantly different between both groups (17% of CLD patients vs. 58% in the general cohort, <i>p</i> = 0.01). Four patients with CLD received >1 FMT, of which 2 did not respond to treatment. There was no significant difference between patients with liver disease and the rest of the cohort with regard to FMT response (12/14 (87%) vs. 164/187 (88%), <i>p</i> = 0.01). Four patients with CLD received >1 FMT, of which 2 did not respond to treatment. There was no significant difference between patients with liver disease and the rest of the cohort with regard to FMT response (12/14 (87%) vs. 164/187 (88%).</p><p><strong>Conclusion: </strong>FMT is a safe and effective therapy against CDI for patients with CLD and cirrhosis.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"1874570"},"PeriodicalIF":1.8,"publicationDate":"2020-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/1874570","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37634072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies.","authors":"Fred Poordad,&nbsp;Norah A Terrault,&nbsp;Naim Alkhouri,&nbsp;Wei Tian,&nbsp;Lee F Allen,&nbsp;Mordechai Rabinovitz","doi":"10.1155/2020/5421632","DOIUrl":"https://doi.org/10.1155/2020/5421632","url":null,"abstract":"<p><strong>Aims: </strong>Thrombocytopenia complicates the management of patients with chronic liver disease (CLD) undergoing invasive procedures with a bleeding risk. Until recently, prophylactic platelet transfusion was the only treatment option, but has significant safety and efficacy limitations. Phase 3 data demonstrated the superiority of avatrombopag to placebo in reducing platelet transfusions for bleeding, supporting its recent approval.</p><p><strong>Methods: </strong>Integrated analyses of pooled data (<i>N</i> = 435) from two randomized, double-blind, placebo-controlled, phase 3 studies assessed the original efficacy endpoints. Additional analyses included subgroup analyses, alternate Baseline platelet count definitions, and another efficacy endpoint.</p><p><strong>Results: </strong>Avatrombopag was superior to placebo in increasing patients not requiring a platelet transfusion or rescue procedure, those achieving a platelet count ≥50 × 10⁹/L on Procedure Day, and the change in platelet counts from Baseline. The avatrombopag treatment effect was consistently positive across clinically important disease and Baseline clinical characteristic subgroups, and using alternate Baseline platelet count cohort definitions. Similarly, more avatrombopag-treated patients achieved ≥50 × 10⁹/L platelets with an increase of ≥20 × 10⁹/L from Baseline. The incidence and severity of adverse events were similar between avatrombopag and placebo. Further, safety data demonstrated a low risk for thromboembolic events and hepatotoxicity.</p><p><strong>Conclusion: </strong>These integrated analyses confirmed the superiority of avatrombopag to placebo in reducing platelet transfusions or rescue procedures for bleeding in patients with thrombocytopenia and CLD scheduled to undergo an invasive procedure, and its tolerable safety profile. Importantly, these data warrant reconsideration of clinical decision making regarding the need to treat thrombocytopenia in patients with CLD. This trial was registered with NCT01972529 and NCT01976104.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"5421632"},"PeriodicalIF":1.8,"publicationDate":"2020-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/5421632","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37634073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Study of Protective Effect of Cimetidine and Verapamil on Paracetamol-Induced Hepatotoxicity in Mice.","authors":"Lubna Danish,&nbsp;Riffat Siddiq,&nbsp;Sarwat Jahan,&nbsp;Mehwish Taneez,&nbsp;Manzoor Khan,&nbsp;Marva Sandhu","doi":"10.1155/2020/9185361","DOIUrl":"https://doi.org/10.1155/2020/9185361","url":null,"abstract":"<p><p>Paracetamol, chemically known as acetaminophen, if taken in higher doses has hepatotoxic potential. Cimetidine by inhibiting the cytochromal enzymes and reducing the production of the toxic metabolite can reduce the hepatotoxic potential while Verapamil can act as a hepatoprotective by maintaining calcium homeostasis. The present study was conducted to study the hepatoprotective activity of Cimetidine and Verapamil against the toxicity induced by paracetamol. In addition to the group receiving only distilled water or 300 mg/kg paracetamol additional groups were added treated with 150 mg/kg Cimetidine and Verapamil alone or both. The Liver function tests and histopathology revealed hepatotoxicity in the group receiving paracetamol (PCM) while normal parameters were observed in the groups receiving Cimetidine and Verapamil. Our results strongly suggested that Cimetidine and Verapamil possess hepatoprotective potential against paracetamol induced hepatotoxicity.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"9185361"},"PeriodicalIF":1.8,"publicationDate":"2020-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/9185361","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37677199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}